ESJAY PHARMA is a major pharmaceutical company focused on Metabolic, Oncology, Neurology.
ESJAY PHARMA's Key Drugs
ESJAY PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ESJAY PHARMA's Recent FDA Approvals
New NDA/BLA approvals for ESJAY PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
ESJAY PHARMA's Therapeutic Areas
ESJAY PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Oncology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ESJAY PHARMA's Top Competitors
ESJAY PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ESJAY PHARMA Pipeline Snapshot
Active clinical trials for ESJAY PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1941-01-11
- Latest
- 2026-11-03
- Applications
- 8